A Phase 1/2 interventional study of Acalabrutinib in Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and Richter's Syndrome, sponsored by Acerta Pharma BV. Active, not recruiting at 12 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 7th largest by enrollment, is the only one that started in 2014, is one of 4 in phase 1/2, reaches primary completion later than 3 of the 27 other live ones, and was the 1st registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Austria, Brazil and 6 more countries
Ages 18–130
Zulfa Omer · Sites in United States
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Seema Bhat · Sites in United States
Ages 18+
By country, each count listing its studies:
acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 26 · Phase 3 9 · Phase 4 1
First in 2014; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 306 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 61 across the 39 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca: 6 open now, 21 under way, 5 of them phase 3. Of 18 finished, 10 (56%) have results posted.
Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, this one is the 8th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2014, is one of 10 in phase 1/2, reaches primary completion later than 4 of the 20 other live ones, and was the 8th registered.
AstraZeneca’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2005.
9 of the studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05057494Phase 3AstraZenecaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-07-15 |
| NCT05971251University of Alabama at BirminghamAddition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia | 2026-12-31 |
| NCT06757647Seema BhatAcalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 2026-12-31 |
| NCT05943496OHSU Knight Cancer InstituteTafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | 2027-01-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among AstraZeneca’s 42 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Inclusion Criteria:
Active disease meeting ≥ 1 of the following International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria for requiring treatment:
i. Unintentional weight loss ≥ 10% within the previous 6 months before screening.
ii. Fevers higher than 100.5°F or 38.0°C for 2 or more weeks before screening without evidence of infection.
iii. Night sweats for > 1 month before screening without evidence of infection.
Inclusion Criteria for Treatment Subgroups
Exclusion Criteria:
10. Central nervous system (CNS) involvement by lymphoma. 11. Grade ≥ 2 toxicity (other than alopecia) continuing from prior anticancer therapy including radiation.
12. Known history of (HIV) or serologic status indicating active virus (HCV) or virus (HBV) infection or any uncontrolled active systemic infection. Participants with hepatitis B core antibody positive who are surface antigen negative or who are hepatitis C antibody positive will need to have a negative polymerase chain reaction (PCR) result before enrollment. Those who are hepatitis B surface antigen positive or hepatitis B PCR positive and those who are hepatitis C PCR positive will be excluded.
13. Uncontrolled autoimmune hemolytic anemia (AIHA) or immune thrombocytopenic purpura (ITP) defined as declining hemoglobin or platelet count secondary to autoimmune destruction within the screening period or requirement for high doses of (> 20 mg daily of prednisone daily or equivalent).
14. History of stroke or intracranial hemorrhage within 6 months prior to the first dose of study drug.
15. Requires treatment with proton-pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole).
16. Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within 7 days of first dose of study drug.
17. Major surgery within 4 weeks before first dose of study drug. 18. ANC \< 0.75 x 10\^9/L or platelet count \< 50 x 10\^9/L unless there is bone marrow involvement.
19. Total > 1.5 x (ULN) (total bilirubin ≤ 2.5 x ULN allowed in participants with autoimmune hemolytic anemia that is otherwise controlled); and (AST) or alanine aminotransferase (ALT) > 3.0 x ULN unless disease related.
20. Serum amylase > 1.5 x ULN or serum lipase > 1.5 x ULN. 21. Significant screening (ECG) abnormalities including, 2nd degree AV block type II, 3rd degree block, Grade 2 or higher bradycardia, or ≥ 480 ms.
22. Cardiac troponin I levels above the limit of normal as specified by the manufacturer.
23. Breast feeding or pregnant. 24. History of bleeding diathesis (eg, hemophilia, von Willebrand disease). 25. Concurrent participation in another therapeutic clinical trial. 26. Estimated of \< 30 mL/min, calculated using the formula of Cockcroft and Gault [(140-Age) • Mass (kg)/(72 • creatinine mg/dL); multiply by 0.85 if female].
27. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1 (dose-escalation) and Phase 2 (dose-expansion) will be conducted for participants with relapsed/refractory CLL or SLL. In Phase 1, participants will receive oral once daily (QD) acalabrutinib at Dose 1 (Cohort 1), Dose 2 (Cohort 2a), Dose 3 (Cohort 3), and Dose 4 (Cohort 4a), and twice daily (BID) acalabrutinib at Dose 1 (Cohort 2b) and Dose 5 (Cohort 4b) for 28 days (1 cycle). In Phase 2, participants will receive oral acalabrutinib at Dose 1 BID (Cohort 2b) or Dose 5 QD (Cohort 2c, later will be switched to Dose 1 BID per protocol amendment 6) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest. Participants from Phase 1 will be continued to receive Dose 1 BID until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
Drug: Acalabrutinib
Treatment-naïve participants with confirmed CLL or SLL, will receive oral acalabrutinib Dose 5 QD (Cohort 7, later will be switched to Dose 1 BID per protocol amendment 6) or Dose 1 BID (Cohort 11) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
Drug: Acalabrutinib
Participants with confirmed CLL or SLL and were not tolerating ibrutinib treatment, will receive oral acalabrutinib Dose 5 QD (Cohort 8a, later switched to Dose 1 BID per protocol amendment 4) or Dose 1 BID (Cohort 8b) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
Drug: Acalabrutinib
Participants with diffuse large B-cell lymphoma (DLBCL) Richter's transformation (RS) or prolymphocytic leukemia (PLL) transformation, will receive oral acalabrutinib Dose 5 BID (Cohort 9) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
Drug: Acalabrutinib
Participants with confirmed CLL/SLL and had relapsed/refractory to ibrutinib treatment, will receive oral acalabrutinib Dose 5 QD (Cohort 10) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
Drug: Acalabrutinib
Participants will receive acalabrutinib as stated in the arms' description.
Also known as: ACP-196
Number of Participants With Dose Limiting Toxicities (DLTs) in Phase 1
Participants with DLTs in Phase 1 are reported. The DLT was defined as any of the following events unless the adverse event is clearly related to disease progression or the participant's current medical history and associated comorbidities: (1) Any Grade 3 or greater nonhematologic toxicity with the exceptions of alopecia and Grade 3 nausea, vomiting, and diarrhea that respond to supportive therapy; (2) Hematologic toxicities including Grade 4 neutropenia lasting more than 5 days, Grade 4 or Grade 3 thrombocytopenia with bleeding or any requirement for platelets transfusion, Grade 3 or greater febrile neutropenia (body temperature of 38.5 degrees Celsius or more), or Grade 4 anemia, unexplained by underlying disease; or (3) Dosing delay due to toxicity for \> 7 consecutive days.
Time frame: From Day 1 to Day 28 after first dose of study drug
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
Time frame: Day 1 through the final data cutoff date (approximately 7 years 6 months)
Number of Participants With Treatment Emergent Events of Clinical Interest (ECI)
The treatment emergent ECI included the events identified based on preclinical findings, emerging data from clinical studies relating to acalabrutinib, and pharmacological effects of approved Bruton's tyrosine kinase (BTK) inhibitors and reported after the first dose of the study drug.
Time frame: Day 1 through the final data cutoff date (approximately 7 years 6 months)
Number of Participants With Clinically Important Laboratory Abnormalities With Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or More
Participants with clinically important laboratory abnormalities with CTCAE Grade 3 or more are reported. Laboratory analysis included hematology, clinical chemistry, amylase, lipase, cardiac troponin I, hepatitis B and C testing, and urinalysis. The CTCAE version 4.03 is a descriptive terminology is used for AE reporting. The CTCAE v4.03 displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 3 as severe AE, Grade 4 as life-threatening or disabling AE, and Grade 5 as death related to AE.
Time frame: Day 1 through the final data cutoff date (approximately 7 years 6 months)
Number of Participants With Clinically Abnormal Vital Signs Reported as TEAEs
Participants with clinically abnormal vital signs (blood pressure, respiratory rate, pulse rate, or body temperature) reported as TEAEs are reported.
Time frame: Day 1 through the final data cutoff date (approximately 7 years 6 months)
Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours (AUC0-6) of Acalabrutinib
The AUC0-6 of acalabrutinib is reported.
Time frame: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours postdose on Day 1 and Day 8
Area Under the Plasma Concentration-time Curve From Time 0 to Last Measurable Concentration (AUC0-last) of Acalabrutinib
The AUC0-last of acalabrutinib is reported.
Time frame: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Acalabrutinib
The AUC0-inf of Acalabrutinib is reported.
Time frame: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8
Maximum Observed Plasma Concentration (Cmax) of Acalabrutinib
The Cmax of Acalabrutinib is reported.
Time frame: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8
Time of Maximum Plasma Concentration (Tmax) of Acalabrutinib
The Tmax of Acalabrutinib is reported.
Time frame: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8
Terminal Elimination Half-life (t1/2) of Acalabrutinib
The t1/2 of acalabrutinib is reported.
Time frame: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8
Terminal Elimination Rate Constant (λz) of Acalabrutinib
The λz of acalabrutinib is reported.
Time frame: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8
Apparent Oral Clearance (CL/F) of Acalabrutinib
The CL/F of acalabrutinib is reported.
Time frame: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8
Apparent Volume of Distribution (Vz/F) of Acalabrutinib
The Vz/F of acalabrutinib is reported.
Time frame: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8
Percentage of Participants With Objective Response (OR) as Assessed by the Investigator
For CLL/SLL, OR is defined as complete remission (CR), CR with incomplete marrow recovery (CRi), or partial remission (PR). CR: lymphocytes (lympho) \<4×10\^9/L, normocellular bone marrow (BM), normal lymph nodes (NLN), liver and spleen (L/S), absolute neutrophil count (ANC) \>1.5×10\^9/L, platelets \>100×10\^9/L, hemoglobin (Hb) \>11g/dL. Cri: lympho \<4×10\^9/L, hypocellular BM, NLN, L/S, persistent anemia, hrombocytopenia, or neutropenia. PR: \>=50% reduction in lymphadenopathy and/or enlargement of L/S or lympho (\<5×10\^9/L or \>=50% decrease from baseline) and criteria of ANC/platelets/Hb per CR or \>=50% improvement over baseline. Hematology result were without exogenous growth factors/transfusion. For RS, OR as CR or PR by Cheson et al. 2014 based on PET/CT scans and bone marrow. CR: disappearance of all detectable clinical evidence of disease and disease-related symptoms and PR: \>=50% decrease in sum of the product diameter of 6 largest nodal masses and no new sites of disease.
Time frame: Day 1 through the final data cutoff date (approximately 7 years 6 months)
Duration of Response (DOR) as Assessed by the Investigator
The DoR is defined as the time from the date of achieving the first CR, CRi, or PR to the date of progressive disease (PD) or death due to any cause, whichever occurred first. The CR, CRi, or PR are defined in the above outcome measure. For CLL/SLL, PD is defined as lympho \>=50% increase from baseline with \>= 5000 B lymphocytes/µL, progressive cytopenias by bone marrow biopsy, appearance of any new lesion or new appearance of hepatomegaly or splenomegaly or \>= 50 % increase in lymphadenopathy/hepatomegaly/splenomegaly, platelets decrease of \>=50% from baseline secondary to CLL or \< 100,000/µL and worsening bone marrow or Hb decrease of \> 2 g/dL from baseline secondary to CLL or decrease to less than 100 g/L and worsening bone marrow. For RS, PD is defined as an increase by 25 % in longest diameter, new lesion or assessable disease progression. The DoR was estimated using Kaplan-Meier method.
Time frame: Day 1 through the final data cutoff date (approximately 7 years 6 months)
Progression Free Survival (PFS) as Assessed by the Investigator
The PFS is defined as the time from the date of first dose of study drug to the date of first PD or death due to any cause, whichever occurred first. For CLL/SLL, PD is defined as lympho \>= 50 % increase from baseline with \>= 5000 B lymphocytes/µL, progressive cytopenias by bone marrow biopsy, appearance of any new lesion or new appearance of hepatomegaly or splenomegaly or \>= 50 % increase in lymphadenopathy/hepatomegaly/splenomegaly, platelets decrease of \>= 50 % from baseline secondary to CLL or \< 100,000/µL and worsening bone marrow or Hb decrease of \> 2 g/dL from baseline secondary to CLL or decrease to less than 100 g/L and worsening bone marrow. For RS, PD is defined as an increase by 25 % in longest diameter, new lesion or assessable disease progression. The PFS was estimated using Kaplan-Meier method.
Time frame: Day 1 through the final data cutoff date (approximately 7 years 6 months)
| Milestone | Relapsed/Refractory Cohort | Treatment-naive Cohort | Ibrutinib-intolerant Cohort | Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort | Ibrutinib Relapsed/Refractory Cohort |
|---|---|---|---|---|---|
| Started | 134 | 99 | 33 | 29 | 6 |
| Completed | 41 | 70 | 6 | 3 | 0 |
| Not completed | 93 | 29 | 27 | 26 | 6 |
| Withdrew: Completed 30-day safety follow-up visit | 53 | 16 | 12 | 2 | 1 |
| Withdrew: Death | 13 | 2 | 2 | 11 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Started other anti-cancer therapy | 17 | 4 | 7 | 9 | 3 |
| Withdrew: Withdrawal by subject | 3 | 1 | 1 | 1 | 0 |
| Withdrew: Other | 6 | 6 | 4 | 2 | 0 |
Participants with DLTs in Phase 1 are reported. The DLT was defined as any of the following events unless the adverse event is clearly related to disease progression or the participant's current medical history and associated comorbidities: (1) Any Grade 3 or greater nonhematologic toxicity with the exceptions of alopecia and Grade 3 nausea, vomiting, and diarrhea that respond to supportive therapy; (2) Hematologic toxicities including Grade 4 neutropenia lasting more than 5 days, Grade 4 or Grade 3 thrombocytopenia with bleeding or any requirement for platelets transfusion, Grade 3 or greater febrile neutropenia (body temperature of 38.5 degrees Celsius or more), or Grade 4 anemia, unexplained by underlying disease; or (3) Dosing delay due to toxicity for \> 7 consecutive days.
| Participants | Cohort 1 | Cohort 2a | Cohort 2b | Cohort 3 | Cohort 4a | Cohort 4b |
|---|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) in Phase 1 | 0 | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
| Participants | Relapsed/Refractory Cohort | Treatment-naive Cohort | Ibrutinib-intolerant Cohort | Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort | Ibrutinib Relapsed/Refractory Cohort |
|---|---|---|---|---|---|
| Any TEAEs | 134 | 99 | 33 | 28 | 6 |
| Any TESAEs | 86 | 50 | 20 | 18 | 3 |
The treatment emergent ECI included the events identified based on preclinical findings, emerging data from clinical studies relating to acalabrutinib, and pharmacological effects of approved Bruton's tyrosine kinase (BTK) inhibitors and reported after the first dose of the study drug.
| Participants | Relapsed/Refractory Cohort | Treatment-naive Cohort | Ibrutinib-intolerant Cohort | Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort | Ibrutinib Relapsed/Refractory Cohort |
|---|---|---|---|---|---|
| Atrial fibrillation | 12 | 6 | 4 | 3 | 0 |
| Ventricular tachyarrhythmias | 2 | 0 | 0 | 0 | 0 |
| Anemia | 22 | 10 | 4 | 10 | 1 |
| Neutropenia | 26 | 9 | 5 | 13 | 1 |
| Other Leukopenia | 2 | 1 | 1 | 0 | 0 |
| Thrombocytopenia | 10 | 1 | 4 | 4 | 0 |
| Major hemorrhage | 11 | 8 | 4 | 0 | 1 |
| Hepatotoxicity | 4 | 4 | 1 | 3 | 0 |
| Hypertension | 31 | 29 | 7 | 2 | 0 |
| Infections | 118 | 86 | 25 | 18 | 4 |
| Interstitial lung disease/Pneumonitis | 1 | 3 | 0 | 0 | 0 |
| Second primary malignancies, excluding non-melanoma skin | 23 | 14 | 3 | 1 | 0 |
| Tumor lysis syndrome | 1 | 0 | 0 | 0 | 0 |
Participants with clinically important laboratory abnormalities with CTCAE Grade 3 or more are reported. Laboratory analysis included hematology, clinical chemistry, amylase, lipase, cardiac troponin I, hepatitis B and C testing, and urinalysis. The CTCAE version 4.03 is a descriptive terminology is used for AE reporting. The CTCAE v4.03 displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 3 as severe AE, Grade 4 as life-threatening or disabling AE, and Grade 5 as death related to AE.
| Participants | Relapsed/Refractory Cohort | Treatment-naive Cohort | Ibrutinib-intolerant Cohort | Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort | Ibrutinib Relapsed/Refractory Cohort |
|---|---|---|---|---|---|
| Hemoglobin, platelets or neutrophils decreased | 72 | 30 | 14 | 19 | 4 |
| Absolute neutrophil count (decreased) | 57 | 23 | 11 | 13 | 3 |
| Hemoglobin (decreased) | 17 | 5 | 3 | 8 | 3 |
| Platelets (decreased) | 20 | 3 | 4 | 5 | 1 |
| Leukocytes (decreased) | 12 | 2 | 3 | 6 | 0 |
| Leukocytes (increased) | 29 | 21 | 7 | 0 | 2 |
| Absolute lymphocyte count (decreased) | 20 | 7 | 2 | 6 | 0 |
| Absolute lymphocyte count (increased) | 29 | 8 | 7 | 3 | 1 |
| Urate (increased) | 24 | 15 | 8 | 5 | 2 |
| Sodium (decreased) | 12 | 5 | 2 | 3 | 0 |
| Phosphate (decreased) | 9 | 1 | 1 | 1 | 0 |
| Potassium (increased) | 3 | 5 | 1 | 0 | 0 |
| Glucose (increased) | 3 | 1 | 3 | 0 | 0 |
| Alanine aminotransferase (increased) | 3 | 1 | 1 | 1 | 0 |
| Calcium (increased) | 5 | 0 | 0 | 1 | 0 |
| Aspartate aminotransferase (increased) | 2 | 2 | 0 | 0 | 0 |
| Magnesium (increased) | 2 | 2 | 0 | 0 | 0 |
| Potassium (decreased) | 2 | 1 | 0 | 1 | 0 |
| Albumin (decreased) | 2 | 1 | 0 | 0 | 0 |
| Calcium (decreased) | 2 | 0 | 0 | 1 | 0 |
| Alkaline phosphatase (increased) | 1 | 0 | 0 | 1 | 0 |
| Amylase (increased) | 2 | 0 | 0 | 0 | 0 |
| Bilirubin (increased) | 2 | 0 | 0 | 0 | 0 |
| Creatinine (increased) | 2 | 0 | 0 | 0 | 0 |
| Lipase (increased) | 1 | 1 | 0 | 0 | 0 |
Participants with clinically abnormal vital signs (blood pressure, respiratory rate, pulse rate, or body temperature) reported as TEAEs are reported.
| Participants | Relapsed/Refractory Cohort | Treatment-naive Cohort | Ibrutinib-intolerant Cohort | Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort | Ibrutinib Relapsed/Refractory Cohort |
|---|---|---|---|---|---|
| Tachycardia | 3 | 8 | 2 | 3 | 0 |
| Bradycardia | 6 | 1 | 0 | 0 | 0 |
| Pyrexia | 39 | 14 | 10 | 6 | 0 |
| Hyperpyrexia | 0 | 0 | 0 | 1 | 0 |
| Hypothermia | 0 | 1 | 0 | 0 | 0 |
| Procedural hypotension | 0 | 1 | 0 | 0 | 0 |
| Blood pressure increased | 0 | 1 | 0 | 0 | 0 |
| Dyspnoea | 27 | 18 | 6 | 3 | 2 |
| Dyspnoea exertional | 5 | 5 | 1 | 0 | 1 |
| Hypertension | 30 | 28 | 6 | 1 | 0 |
| Hypotension | 7 | 12 | 5 | 1 | 2 |
| Orthostatic hypotension | 0 | 5 | 1 | 0 | 0 |
| Essential hypertension | 0 | 0 | 1 | 0 | 0 |
| Hypertensive crisis | 1 | 0 | 0 | 0 | 0 |
| Malignant hypertension | 0 | 0 | 0 | 1 | 0 |
| Palpitations | 13 | 4 | 0 | 0 | 0 |
The AUC0-6 of acalabrutinib is reported.
| hr*ng/mL | Cohort 1 | Cohort 2a | Cohort 2b | Cohort 2c | Cohort 3 | Cohort 4a | Cohort 4b | Cohort 7 | Cohort 8a | Cohort 8b | Cohort 9 | Cohort 10 | Cohort 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 971 ± 564 | 1250 ± 836 | 819 ± 493 | 2170 ± 1180 | 1880 ± 1810 | 2960 ± 1570 | 1950 ± 487 | 1740 ± 1540 | 362 ± 221 | 670 ± 471 | 1690 ± 849 | 1100 ± 590 | 789 ± 398 |
| Day 8 | 631 ± 193 | 1180 ± 859 | 858 ± 419 | 1660 ± 554 | 1750 ± 518 | 1630 ± 1050 | 1690 ± 1090 | 1480 ± 986 | 2080 ± NA | 834 ± 713 | 1860 ± 786 | 1250 ± 1050 | 642 ± 310 |
The AUC0-last of acalabrutinib is reported.
| hr*ng/mL | Cohort 1 | Cohort 2a | Cohort 2b | Cohort 2c | Cohort 3 | Cohort 4a | Cohort 4b | Cohort 7 | Cohort 8a | Cohort 8b | Cohort 9 | Cohort 10 | Cohort 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 1030 ± 529 | 1270 ± 775 | 795 ± 502 | 2280 ± 1060 | 2030 ± 1670 | 3430 ± 1640 | 1950 ± 487 | 1790 ± 1470 | 539 ± 106 | 570 ± 451 | 1860 ± 1570 | 1100 ± 590 | 850 ± 462 |
| Day 8 | 729 ± 380 | 1180 ± 861 | 850 ± 660 | 1850 ± 882 | 2020 ± 1170 | 1750 ± 979 | 1560 ± 1020 | 1400 ± 929 | 1180 ± NA | 748 ± 701 | 1710 ± 669 | 1260 ± 1060 | 660 ± 294 |
The AUC0-inf of Acalabrutinib is reported.
| hr*ng/mL | Cohort 1 | Cohort 2a | Cohort 2b | Cohort 2c | Cohort 3 | Cohort 4a | Cohort 4b | Cohort 7 | Cohort 8a | Cohort 8b | Cohort 9 | Cohort 10 | Cohort 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 1040 ± 534 | 1320 ± 827 | 855 ± 517 | 2440 ± 1010 | 2050 ± 1680 | 3250 ± 1630 | 1970 ± 495 | 1910 ± 1530 | 574 ± 76.3 | 801 ± 410 | 1770 ± 776 | 1350 ± 373 | 940 ± 430 |
| Day 8 | 621 ± 187 | 1200 ± 865 | 956 ± 665 | 1990 ± 1020 | 2360 ± 1210 | 1750 ± 1140 | 1780 ± 1230 | 1540 ± 973 | 2120 ± NA | 963 ± 728 | 1750 ± 701 | 1580 ± 1030 | 652 ± 298 |
The Cmax of Acalabrutinib is reported.
| ng/mL | Cohort 1 | Cohort 2a | Cohort 2b | Cohort 2c | Cohort 3 | Cohort 4a | Cohort 4b | Cohort 7 | Cohort 8a | Cohort 8b | Cohort 9 | Cohort 10 | Cohort 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 685 ± 475 | 754 ± 540 | 706 ± 499 | 1950 ± 1460 | 1350 ± 1170 | 1550 ± 1230 | 1600 ± 291 | 1390 ± 1260 | 206 ± 240 | 554 ± 500 | 1190 ± 925 | 727 ± 436 | 930 ± 595 |
| Day 8 | 521 ± 308 | 805 ± 757 | 812 ± 829 | 1350 ± 809 | 1350 ± 933 | 902 ± 638 | 1320 ± 1540 | 1020 ± 747 | 939 ± NA | 616 ± 660 | 1460 ± 913 | 610 ± 751 | 633 ± 449 |
The Tmax of Acalabrutinib is reported.
| Hours | Cohort 1 | Cohort 2a | Cohort 2b | Cohort 2c | Cohort 3 | Cohort 4a | Cohort 4b | Cohort 7 | Cohort 8a | Cohort 8b | Cohort 9 | Cohort 10 | Cohort 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 1.01 (0.417 to 2.00) | 0.917 (0.500 to 3.83) | 0.750 (0.500 to 2.30) | 1.00 (0.250 to 5.92) | 1.00 (0.500 to 1.83) | 1.00 (0.750 to 4.00) | 0.758 (0.250 to 1.08) | 0.783 (0.250 to 2.10) | 1.30 (0.750 to 2.20) | 0.783 (0.500 to 5.83) | 0.992 (0.500 to 4.05) | 1.00 (0.500 to 1.08) | 0.642 (0.483 to 2.00) |
| Day 8 | 1.05 (0.500 to 1.17) | 0.517 (0.467 to 1.00) | 0.750 (0.450 to 5.75) | 1.03 (0.500 to 2.10) | 1.00 (0.500 to 1.97) | 0.700 (0.500 to 1.95) | 0.758 (0.500 to 2.07) | 0.750 (0.250 to 2.22) | 1.49 (1.08 to 1.90) | 0.908 (0.467 to 2.03) | 1.00 (0.500 to 2.08) | 1.58 (0.467 to 4.08) | 0.533 (0.250 to 1.85) |
The t1/2 of acalabrutinib is reported.
| Hours | Cohort 1 | Cohort 2a | Cohort 2b | Cohort 2c | Cohort 3 | Cohort 4a | Cohort 4b | Cohort 7 | Cohort 8a | Cohort 8b | Cohort 9 | Cohort 10 | Cohort 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 1.48 ± 1.50 | 1.44 ± 1.60 | 0.914 ± 0.452 | 0.993 ± 0.303 | 2.89 ± 3.12 | 3.52 ± 4.93 | 0.869 ± 0.0811 | 1.41 ± 1.73 | 4.83 ± 3.69 | 0.900 ± 0.140 | 0.798 ± 0.0973 | 1.01 ± 0.209 | 0.781 ± 0.137 |
| Day 8 | 1.09 ± 0.216 | 0.942 ± 0.107 | 0.995 ± 0.621 | 0.902 ± 0.187 | 0.886 ± 0.131 | 1.38 ± 0.546 | 1.13 ± 0.408 | 1.02 ± 0.454 | 0.914 ± NA | 1.25 ± 0.494 | 0.867 ± 0.289 | 1.67 ± 1.41 | 0.811 ± 0.174 |
The λz of acalabrutinib is reported.
| 1/hr | Cohort 1 | Cohort 2a | Cohort 2b | Cohort 2c | Cohort 3 | Cohort 4a | Cohort 4b | Cohort 7 | Cohort 8a | Cohort 8b | Cohort 9 | Cohort 10 | Cohort 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 0.679 ± 0.276 | 0.750 ± 0.307 | 0.848 ± 0.214 | 0.755 ± 0.209 | 0.502 ± 0.300 | 0.557 ± 0.386 | 0.804 ± 0.0793 | 0.756 ± 0.292 | 0.373 ± 0.468 | 0.784 ± 0.112 | 0.880 ± 0.114 | 0.706 ± 0.144 | 0.916 ± 0.177 |
| Day 8 | 0.655 ± 0.132 | 0.744 ± 0.0866 | 0.793 ± 0.191 | 0.798 ± 0.161 | 0.797 ± 0.128 | 0.578 ± 0.243 | 0.679 ± 0.251 | 0.745 ± 0.174 | 0.758 ± NA | 0.623 ± 0.218 | 0.857 ± 0.209 | 0.603 ± 0.324 | 0.894 ± 0.204 |
The CL/F of acalabrutinib is reported.
| L/hr | Cohort 1 | Cohort 2a | Cohort 2b | Cohort 2c | Cohort 3 | Cohort 4a | Cohort 4b | Cohort 7 | Cohort 8a | Cohort 8b | Cohort 9 | Cohort 10 | Cohort 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 114 ± 44.4 | 193 ± 121 | 212 ± 302 | 112 ± 98.4 | 265 ± 263 | 169 ± 123 | 108 ± 32.0 | 315 ± 488 | 352 ± 43.7 | 311 ± 166 | 142 ± 88.9 | 156 ± 40.3 | 137 ± 77.4 |
| Day 8 | 176 ± 62.1 | 216 ± 154 | 162 ± 141 | 122 ± 55.5 | 131 ± 70.3 | 344 ± 242 | 191 ± 180 | 389 ± 1070 | 94.5 ± NA | 336 ± 258 | 132 ± 51.8 | 167 ± 95.1 | 188 ± 92.5 |
The Vz/F of acalabrutinib is reported.
| L | Cohort 1 | Cohort 2a | Cohort 2b | Cohort 2c | Cohort 3 | Cohort 4a | Cohort 4b | Cohort 7 | Cohort 8a | Cohort 8b | Cohort 9 | Cohort 10 | Cohort 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 268 ± 332 | 574 ± 992 | 450 ± 1250 | 182 ± 230 | 2100 ± 3290 | 1480 ± 2850 | 133 ± 30.0 | 930 ± 1750 | 2600 ± 2030 | 422 ± 290 | 171 ± 125 | 235 ± 105 | 158 ± 102 |
| Day 8 | 286 ± 150 | 302 ± 238 | 333 ± 729 | 165 ± 104 | 172 ± 114 | 739 ± 745 | 384 ± 466 | 1180 ± 4940 | 125 ± NA | 726 ± 814 | 179 ± 134 | 533 ± 716 | 234 ± 162 |
For CLL/SLL, OR is defined as complete remission (CR), CR with incomplete marrow recovery (CRi), or partial remission (PR). CR: lymphocytes (lympho) \<4×10\^9/L, normocellular bone marrow (BM), normal lymph nodes (NLN), liver and spleen (L/S), absolute neutrophil count (ANC) \>1.5×10\^9/L, platelets \>100×10\^9/L, hemoglobin (Hb) \>11g/dL. Cri: lympho \<4×10\^9/L, hypocellular BM, NLN, L/S, persistent anemia, hrombocytopenia, or neutropenia. PR: \>=50% reduction in lymphadenopathy and/or enlargement of L/S or lympho (\<5×10\^9/L or \>=50% decrease from baseline) and criteria of ANC/platelets/Hb per CR or \>=50% improvement over baseline. Hematology result were without exogenous growth factors/transfusion. For RS, OR as CR or PR by Cheson et al. 2014 based on PET/CT scans and bone marrow. CR: disappearance of all detectable clinical evidence of disease and disease-related symptoms and PR: \>=50% decrease in sum of the product diameter of 6 largest nodal masses and no new sites of disease.
| Percentage of participants | Cohort 1 | Cohort 2a | Cohort 2b | Cohort 2c | Cohort 3 | Cohort 4a | Cohort 4b | Cohort 7 | Cohort 11 |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Objective Response (OR) as Assessed by the Investigator | 100.0 (63.1 to 100.0) | 75 (34.9 to 96.8) | 92.1 (82.4 to 97.4) | 93.8 (79.2 to 99.2) | 100.0 (59.0 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (54.1 to 100.0) | 97.3 (85.8 to 99.9) | 100.0 (94.0 to 100.0) |
The DoR is defined as the time from the date of achieving the first CR, CRi, or PR to the date of progressive disease (PD) or death due to any cause, whichever occurred first. The CR, CRi, or PR are defined in the above outcome measure. For CLL/SLL, PD is defined as lympho \>=50% increase from baseline with \>= 5000 B lymphocytes/µL, progressive cytopenias by bone marrow biopsy, appearance of any new lesion or new appearance of hepatomegaly or splenomegaly or \>= 50 % increase in lymphadenopathy/hepatomegaly/splenomegaly, platelets decrease of \>=50% from baseline secondary to CLL or \< 100,000/µL and worsening bone marrow or Hb decrease of \> 2 g/dL from baseline secondary to CLL or decrease to less than 100 g/L and worsening bone marrow. For RS, PD is defined as an increase by 25 % in longest diameter, new lesion or assessable disease progression. The DoR was estimated using Kaplan-Meier method.
| Months | Cohort 1 | Cohort 2a | Cohort 2b | Cohort 2c | Cohort 3 | Cohort 4a | Cohort 4b | Cohort 7 | Cohort 11 |
|---|---|---|---|---|---|---|---|---|---|
| Duration of Response (DOR) as Assessed by the Investigator | 33.3 (13.8 to NA) | 26.7 (13.9 to NA) | 77.3 (46.3 to NA) | 43.0 (29.4 to NA) | NA (9.0 to NA) | 64.1 (19.4 to NA) | NA (38.9 to NA) | NA (NA to NA) | NA (NA to NA) |
The PFS is defined as the time from the date of first dose of study drug to the date of first PD or death due to any cause, whichever occurred first. For CLL/SLL, PD is defined as lympho \>= 50 % increase from baseline with \>= 5000 B lymphocytes/µL, progressive cytopenias by bone marrow biopsy, appearance of any new lesion or new appearance of hepatomegaly or splenomegaly or \>= 50 % increase in lymphadenopathy/hepatomegaly/splenomegaly, platelets decrease of \>= 50 % from baseline secondary to CLL or \< 100,000/µL and worsening bone marrow or Hb decrease of \> 2 g/dL from baseline secondary to CLL or decrease to less than 100 g/L and worsening bone marrow. For RS, PD is defined as an increase by 25 % in longest diameter, new lesion or assessable disease progression. The PFS was estimated using Kaplan-Meier method.
| Months | Cohort 1 | Cohort 2a | Cohort 2b | Cohort 2c | Cohort 3 | Cohort 4a | Cohort 4b | Cohort 7 | Cohort 11 |
|---|---|---|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) as Assessed by the Investigator | 38.3 (15.5 to NA) | 33.1 (15.8 to NA) | 79.1 (49.8 to NA) | 46.6 (33.9 to NA) | NA (12.7 to NA) | 67.8 (33.2 to NA) | NA (40.7 to NA) | NA (NA to NA) | NA (NA to NA) |
Collected over Day 1 through the final data cutoff date (approximately 7 years 6 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Relapsed/Refractory Cohort | 13/134 (9.7%) | 86/134 (64.2%) | 134/134 (100%) |
| Treatment-naive Cohort | 2/99 (2%) | 50/99 (50.5%) | 99/99 (100%) |
| Ibrutinib-intolerant Cohort | 2/33 (6.1%) | 20/33 (60.6%) | 33/33 (100%) |
| Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort | 11/29 (37.9%) | 18/29 (62.1%) | 28/29 (96.6%) |
| Ibrutinib Relapsed/Refractory Cohort | 2/6 (33.3%) | 3/6 (50%) | 6/6 (100%) |
| Event | Relapsed/Refractory Cohort | Treatment-naive Cohort | Ibrutinib-intolerant Cohort | Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort | Ibrutinib Relapsed/Refractory Cohort |
|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 3/134 | 0/99 | 1/33 | 0/29 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 4/134 | 1/99 | 0/33 | 0/29 | 1/6 |
| SepsisInfections and infestations | 3/134 | 2/99 | 0/33 | 2/29 | 1/6 |
| Septic shockInfections and infestations | 0/134 | 0/99 | 0/33 | 0/29 | 1/6 |
| Upper respiratory tract infectionInfections and infestations | 2/134 | 0/99 | 1/33 | 0/29 | 1/6 |
| Haemorrhage intracranialNervous system disorders | 0/134 | 0/99 | 0/33 | 0/29 | 1/6 |
| PneumoniaInfections and infestations | 19/134 | 6/99 | 3/33 | 1/29 | 0/6 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/134 | 1/99 | 1/33 | 3/29 | 0/6 |
| HypercalcaemiaMetabolism and nutrition disorders | 4/134 | 0/99 | 0/33 | 3/29 | 0/6 |
| FatigueGeneral disorders | 0/134 | 1/99 | 0/33 | 2/29 | 0/6 |
| Event | Relapsed/Refractory Cohort | Treatment-naive Cohort | Ibrutinib-intolerant Cohort | Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort | Ibrutinib Relapsed/Refractory Cohort |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 71/134 | 53/99 | 20/33 | 14/29 | 0/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 47/134 | 55/99 | 9/33 | 6/29 | 0/6 |
| HeadacheNervous system disorders | 68/134 | 48/99 | 14/33 | 12/29 | 1/6 |
| ContusionInjury, poisoning and procedural complications | 42/134 | 50/99 | 11/33 | 5/29 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 54/134 | 49/99 | 15/33 | 3/29 | 1/6 |
| CoughRespiratory, thoracic and mediastinal disorders | 47/134 | 32/99 | 13/33 | 4/29 | 1/6 |
| FatigueGeneral disorders | 49/134 | 22/99 | 7/33 | 6/29 | 1/6 |
| NauseaGastrointestinal disorders | 47/134 | 34/99 | 11/33 | 4/29 | 2/6 |
| HypotensionVascular disorders | 7/134 | 11/99 | 5/33 | 1/29 | 2/6 |
| Weight increasedInvestigations | 34/134 | 33/99 | 10/33 | 0/29 | 0/6 |
All-treated population included all enrolled participants who received 1 or more doses of study drug.
| Age, Continuous(Years) | Relapsed/Refractory Cohort | Treatment-naive Cohort | Ibrutinib-intolerant Cohort | Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort | Ibrutinib Relapsed/Refractory Cohort | Total |
|---|---|---|---|---|---|---|
| Mean | 65.6 ± 9.2 | 63.5 ± 9.7 | 63.9 ± 8.9 | 65.0 ± 9.6 | 62.5 ± 7.9 | 64.6 ± 9.33 |
| Sex: Female, Male(Participants) | Relapsed/Refractory Cohort | Treatment-naive Cohort | Ibrutinib-intolerant Cohort | Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort | Ibrutinib Relapsed/Refractory Cohort | Total |
|---|---|---|---|---|---|---|
| Female | 35 | 33 | 13 | 14 | 3 | 98 |
| Male | 99 | 66 | 20 | 15 | 3 | 203 |
| Ethnicity (NIH/OMB)(Participants) | Relapsed/Refractory Cohort | Treatment-naive Cohort | Ibrutinib-intolerant Cohort | Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort | Ibrutinib Relapsed/Refractory Cohort | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 0 | 0 | 0 | 5 |
| Not Hispanic or Latino | 129 | 94 | 33 | 28 | 6 | 290 |
| Unknown or Not Reported | 3 | 2 | 0 | 1 | 0 | 6 |
| Race (NIH/OMB)(Participants) | Relapsed/Refractory Cohort | Treatment-naive Cohort | Ibrutinib-intolerant Cohort | Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort | Ibrutinib Relapsed/Refractory Cohort | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 1 |
| Asian | 1 | 2 | 0 | 0 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 5 | 2 | 1 | 1 | 15 |
| White | 120 | 88 | 31 | 27 | 5 | 271 |
| More than one race | 6 | 4 | 0 | 1 | 0 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jan 2014 to primary completion in Jul 2021, 89 months.
Results were first posted in Sep 2022, 1 year 1 month after primary completion.
Of 50 industry-sponsored phase 1/2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 104. This study's 89 months is above that.
Counting every sponsor, half of 90 studies reached it within 78 months; a quarter within 51 and three quarters within 103.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib
Leukemia, Lymphocytic, Chronic, B-Cell →